Fecal microbiota transplantation against intestinal colonization by multidrug resistant bacteria

Fecal microbiota transplantation against intestinal colonization by extended spectrum beta-lactamase producing Enterobacteriaceae

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN48328635

Enrollment

Registered

2017-10-11

Start date

2013-05-30

Completion date

Unknown

Last updated

2018-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Extended spectrum beta-lactamase producing Enterobacteriaceae carriership Infections and Infestations

Interventions

Rectal swabs were taken at the moment of inclusion and <1 week before the fecal transplantation. Fecal solution was administered by duodenal tube which was placed by CORTRAK-technology, treatment dura

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients carrying enterobacteriaceae with extended-spectrum beta lactamase (ESBL-EB) on two consecutive cultures, one of which at most 1 week before fecal microbiota transplantation (FMT)

Exclusion criteria

Exclusion criteria: Severe immunodeficiency

Design outcomes

Primary

Measure	Time frame
Negative cultures for ESBL, assessed with MALDI-TOF MS using the Bruker Biotyper (Bruker Daltonics, Germany) and antimicrobial susceptibility testing performed using the VITEK2 system (bioMérieux). Rectal swabs taken at 0, 1, 2, 4 weeks	—

Secondary

Measure	Time frame
Fecal microbiota analyzed by human intestinal tract (HIT-)chip from samples taken at 0 and 4 weeks	—

Countries

Netherlands

Contacts

Public ContactPieter de Groot

p.f.degroot@amc.nl+31 (0)636 123 516

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Mar 7, 2026